Therapeutic Profile Engineering™
The scientific discipline of intentionally engineering therapeutic profiles to preserve efficacy while improving safety, usability, and real-world performance.
FOLAI™ (Fast-Onset, Long-Acting Injectable) Platform
Long-acting injectable delivery engineered for rapid onset and sustained exposure.
In vivo proof-of-concept demonstrated the intended pharmacokinetic profile.
Programs: SOOPR™ Rescue, SOOPR ES™ and FOLAI™ Ketamine.
Evidence Across the Portfolio
O2P™ (Orally Optimized Pharmacokinetics) Platform
A molecular delivery system engineered to control drug exposure and improve safety.
Human proof-of-concept demonstrated pronounced oral overdose protection at supratherapeutic doses while extending duration of action at prescribed doses.
Programs Engineered for Real-World Performance.
Translating Therapeutic Profile Engineering™ into mission-relevant solutions.
Investigational programs; not approved or procurement-ready.
SOOPR™ Rescue
Problem: Naloxone’s effect may not last as long as potent or long-acting opioids, creating a risk of recurrent respiratory depression and repeat dosing.
Therapeutic Profile Engineering™ response: The FOLAI™ platform is being used to engineer rapid onset with sustained naloxone exposure in a single investigational injectable profile.
Intended value: Extend overdose-reversal coverage across a longer danger window.
SOOPR ES™
Problem: High-potency synthetic opioids can produce prolonged or recurrent toxicity, while repeated monitoring and redosing can strain responders in operational and mass-casualty settings.
Therapeutic Profile Engineering™ response: The FOLAI™ platform is being applied to engineer sustained opioid-antagonist exposure in an investigational extended-protection profile.
Intended value: Reduce vulnerability after initial reversal and lessen dependence on repeated intervention.
FOLAI™ Ketamine
Problem: Field use of ketamine may depend on IV access, repeat dosing, infusion equipment and trained monitoring—constraints that become more consequential when evacuation is delayed.
Therapeutic Profile Engineering™ response: The FOLAI™ platform is being used to engineer a rapid-onset, sustained-exposure injectable profile for investigational field analgesia.
Intended value: Enable timely pain control with fewer repeat interventions and less logistical complexity in resource-constrained settings.
Engineering Better Therapeutic Performance.
Elysium applies Therapeutic Profile Engineering™ to create differentiated medicines designed for meaningful performance in the real world. We welcome conversations with strategic partners, investigators and mission-focused collaborators.
Experienced Leadership to Engineer Better Medicines.
Greg Sturmer
Vision • Capital • Execution
Tom Jenkins, PhD
Science • Innovation • Discovery
Board & Advisors
Leadership Track Record
Greg Sturmer — 30 years in healthcare; former Theravance finance and investor-relations leader; former CFO, PharmacoFore.
Tom Jenkins, PhD — 30 years in pharmaceuticals; co-founder, Theravance; former discovery leader, Axys Pharmaceuticals.
Board of Directors
Kathy LaPorte • Bob Rappaport, MD • James Hackworth, PhD • Carey Ng, PhD
Key Advisors
Albert Dahan, MD - FDA collaborator; Expertise; Opioid pharmacology, opioid-induced respiratory depression and its reversal, and ketamine pharmacology
Lynn Webster, MD — Pain physician and researcher
Vern Norviel, JD — Intellectual property counsel